Influence of Immunomodulating Agents Immunovak Vp-4 and Profetal on Functional Activity of Mononuclear Leukocytes

Лебединская, Е. А.; Ахматова, Н. К.; Лебединская, О. В.; Черешнев, В. А.; Родионов, С. Ю.; Киселевский, М. В.

doi:10.15789/1563-0625-2009-1-15-20

Med.Imm.Rus

2014

DOI: 10.15789/1563-0625-2009-1-15-20

|View full text |Cite

Influence of Immunomodulating Agents Immunovak Vp-4 and Profetal on Functional Activity of Mononuclear Leukocytes

Е. А. Лебединская¹,

Н. К. Ахматова²,

О. В. Лебединская³

et al.

Abstract: ВведениеОткрытие молекулярно-клеточных механизмов действия эффекторов системы врожденного иммунитета позволило выдвинуть гипотезу, согласно которой иммунная система распознает и уничтожает аномальные клетки, экспрессирующие опухолевые антигены, приводя к селекции клеток низкоиммуногенных клонов, способных ускользать от иммунного надзора. В связи с этим возникает необходимость более детального изучения роли эффекторов врожденного иммунитета, которые могут распознавать и лизировать дефектные по главному комплекс… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Correction of immune status from hospitalized COVID-19-patients with immunotropic drug added to the basic treatment

Khromova,

Kostinov,

Skhodova

et al. 2023

Med. immunol.

View full text Add to dashboard Cite

Cellular immunity plays an important role in the control of SARS-CoV-2. Lymphopenia and a decrease in the functional activity of cells may be among the main reasons for deterioration of clinical outcomes of the disease. Usage of the bacterial therapeutic vaccine Immunovac-VP-4 during the inflammation phase may be promising for immunomodulation of the cellular immunity. The aim of our study was to evaluate the dynamics of lymphocyte subpopulations in hospitalized patients with COVID-19 upon combining the basic therapy with immunotropic drug based on the antigens from opportunistic pathogens. The study included 45 patients (18-70 years old) admitted with a confirmed diagnosis of moderate/severe infection caused by the COVID-19 virus. In addition to basic therapy, 33 persons of this group received Immunovac-VP-4 by a combined nasal-oral method. Subpopulation activity of peripheral blood lymphocytes in patients over time (at baseline, on the 14th and 30th day after hospitalization) was studied by flow cytometry by means of FC-500 Cytomics (Beckman Coulter, USA) using monoclonal antibodies (mAb) (Immunotech, France). In the group receiving only standard therapy, an increased number of T lymphocytes was detected on day 14 (79.9 (75.5-81.6), p = 0.00252), on day 30 from the start of treatment (78.4 (74.25-79. 2), p = 0.03662), and a decrease in B lymphocytes on day 14 (10.6 (7.78-11.63), p = 0.03236), on day 30 (7.85 (6.25-11.1), p = 0.01352) relative to baseline parameters upon admission. We revealed more pronounced changes in the parameters of cellular immunity relative to the initial parameters, i.e., an increased proportion of T lymphocytes on the 14th day (80.1 (73.8-84.2), p = 0.00018), and 30th day from starting the treatment (80.2 (76-81.9)), T helpers at 14 days after treatment (50.2 (43-57), p = 0.00694), cytotoxic T cells by 30th day of therapy (26.35 (24-29.4), p = 0.0114), decrease in B lymphocytes on day 14 (13.1 (8.2-16.9), p = 0 00158), on the 30th day from the start of treatment (8.2 (7.6-9.7), p <0.00001), and a transient decrease in NK cells on the 14th day (3.7 (2,1-6.3), p = 0.00308), with their recovery on the 30th day of observation to 8.6 (6-12.5) in the Immunovac-VP-4 group. Modulation of cellular immunity may be important for the virus clearance.

show abstract

Correction of immune status from hospitalized COVID-19-patients with immunotropic drug added to the basic treatment

Khromova,

Kostinov,

Skhodova

et al. 2023

Med. immunol.

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Influence of Immunomodulating Agents Immunovak Vp-4 and Profetal on Functional Activity of Mononuclear Leukocytes

Cited by 1 publication

References 0 publications

Correction of immune status from hospitalized COVID-19-patients with immunotropic drug added to the basic treatment

Correction of immune status from hospitalized COVID-19-patients with immunotropic drug added to the basic treatment

Contact Info

Product

Resources

About